International Journal of Healthcare Sciences ISSN 2348-5728 (Online)
Vol. 4, Issue 2, pp: (1795-1801), Month: October 2016 - March 2017, Available at: www.researchpublish.com

Overview of Medication That Induce Leukocytosis

[1]Mohammed Abdullah Mohammed Alkathiri, [2]Riyadh Farraj S Al Areef, [3]Mohanad Jebril Bosily, [4]Saleh Ali M Alsagti, [5]Ahmed Sultan Ahmed AlAmri, [6]Osamah Mohammed Saad Alqahtani, [7]Abdulrahim Moshabbab Hamhom, [8]Asiri, Sultan Abdulwahab M

Abstract: **Leukocytosis has actually been associated with thrombosis and death in cancer patients. We explored the association of leukocytosis with venous thromboembolism (VTE) and early death in cancer patients initiating chemotherapy. Data from a potential, multicenter observational study of treatment-related problems in 4,405 ambulatory cancer patients initiating chemotherapy was utilized for this analysis. The association of leukocytosis, VTE and mortality during the course of chemotherapy was examined in multivariate and univariate analysis.**
In conclusion, Elevated WBC, especially neutrophils, is highly associated with increased threat of VTE and death in cancer patients receiving systemic chemotherapy. Further studies are had to elicit the mechanisms involved.

Keywords: **Venous Thromboembolism (VTE), Medications, induce Leukocytosis.**

1. INTRODUCTION

Leukocytosis has been revealed to be associated with increased threat of both arterial and venous thrombosis in a number of clinical settings including ischemic heart disease [1], cerebrovascular disease [2], and myeloproliferative disorders [3-5] .A raised leukocyte count prior to initiation of chemotherapy was recently determined as one of five clinical elements predictive of increased threat for venous thromboembolism (VTE) in cancer patients [6]. In addition, leukocytosis has been demonstrated to be associated with increased mortality in several subgroups of cancer patients [7-11].Cancer-associated thrombosis is an important problem. Cancer patients are at 2-7 fold increased danger of establishing VTE compared with patients without cancer [12,13] Apoplexy is the second leading cause of death in cancer patients getting chemotherapy 2nd only to disease development [14], and is related to other substantial morbidities consisting of increased threat of bleeding and reoccurring VTE [15-17].

The goal of the current analysis was to identify the relationship between leukocytosis, apoplexy, and early mortality in a big potential observational study of cancer patients starting chemotherapy. A better understanding of the role leukocytes play in cancer progression and thrombosis may guide methods such as targeted thromboprophylaxis which might possibly reduce the incidence of cancer-associated thrombosis.

2. METHODOLOGY

We searched Ovid versions of MEDLINE, EMBASE and PUDMED up to 2015, As well as the Cochrane Database of Systematic Reviews and Cochrane Controlled Trials Register. MESH terms used were ' Leukocytosis' and 'Thrombosis', 'Tumor' and ' venous thromboembolism '. Further terms were included as text words. A high sensitivity "therapy" (trials) filter was applied to the EMBASE search. No other limits were applied to any of the searches. In addition, we hand searched the reference lists of retrieved full-text papers.

3. RESULTS AND DISCUSSION

The research study population made up 4,405 patients with solid tumors or lymphoma enrolled in between March 2002 and October 2005. The typical age of the population was 60 years (variety 18-97, SD 13) and 40% of patients were 65 years of age or older (Table 1). Breast cancer was the most typical solid malignancy, followed by lung and colorectal

cancer. Non-Hodgkin lymphoma was the most typical hematologic malignancy. Since of targeted registration of breast cancer patients, a bulk of the patients were female. Over one-third of the research study population had metastatic disease. Of the 4391 patients with offered standard white blood cell counts, 461 (12.8%) had raised an leukocyte counts.

Table 1 Characteristics of Study Population.

Category All Patients	No. (%) 4405* (100)
Age	
-<65 yrs	2631 (59.7)
-≥65 yrs	1774 (40.3)
Gender	
-Male	1470 (33.4)
-Female	2935 (66.6)
Stage	
-1 to 3	2668 (60.6)
-4	1671 (37.9)
-Unknown	66 (1.5)
Performance status, ECOG	
-0 to 1	3983 (90.5)
-2-4	420 (9.5)
Primary site of cancer	
-Breast	1473 (33.4)
-Colorectal	521 (11.8)
-Lung	907 (20.6)
-Gynecologic	436 (9.9)
-Gastric and pancreatic	90 (2.0)
-Lymphoma	547 (12.4)
-Other solid tumors	431 (9.8)
Comorbidities	
-Cerebrovascular disease	84 (1.9)
-Moderate or severe renal disease -Chronic pulmonary disease	49 (1.1) 364 (8.3)
-Diabetes mellitus	533 (12.1)
-Body mass index ≥ 35 kg/m2	532 (12.1)
-Liver complications	1308 (29.7)
Growth factor/steroid use after chemotherapy initiation	
-Prophylactic Myeloid growth factor	889 (20.2)
-Erythropoiesis-stimulating factor started by cycle 2	1137 (25.8)

Leukocytosis and VTE:

VTE developed in 93 patients (2.1%) over a mean follow-up of 75 days (range 0-384 days). Roughly two-thirds of the occasions were deep vein thrombosis and one-third were pulmonary emboli. The median time from initiation of chemotherapy to development of VTE was 38 days (0-123 days). Sixty eight of 3830 (1.8%) patients with typical pre-chemotherapy leukocyte count established VTE compared to 25 of 561 (4.5%) with raised pre-chemotherapy leukocyte count. The incidence of VTE was highest in those patients with the greatest pre-chemotherapy leukocyte counts. In addition pre-chemotherapy leukocytosis was associated with increased VTE when changed for in a multivariate design consisting of type of malignancy, stage, pre-chemotherapy platelet count, pre chemotherapy hemoglobin level, use of erythropoietic stimulating representatives, and BMI (Hazard Ratio (HR) 2.1, 95% confidence period (CI) 1.3-3.4, p=0.003) (Table 2). The increased danger of VTE with greater leukocyte count persisted while patients were on chemotherapy. After exclud- ing the patients who established VTE or passed away throughout the first cycle, the VTE rate in patients who had consistent leukocytosis after the very first cycle of chemotherapy (3.0%) is considerably higher than the VTE rate in patients whose standard leukocytosis solves (1.7%) and patients with regular leukocyte counts

throughout (1.2%) (P = 0.03 for trend). The mean standard leukocyte count in patients who did not establish VTE prior to initiation of chemotherapy was 8.0 × 109 cells/L compared with 9.6 × 109 cells/L in those that did develop VTE (P = 0.001), and this considerable difference remained prior to subsequent cycles of chemotherapy. Elevation of both absolute neutrophil count (ANC) (N 7.7 × 109 cells/L) and absolute monocyte count (AMC) (N 1.2 × 109 cells/L) prior to initiation of chemotherapy was associated (Pb0.0001 for each) with increased risk of VTE although baseline lymphocytosis (N4.8 × 109 cells/L) was not .

Table 2 Clinical variables associated with VTE by multivariate analysis.

Patient Characteristics	HR	P-value	95 % CI
Site of cancer -Very high risk (stomach, pancreas) High risk (lung, lymphoma, gynecologic, genitourinary excluding prostate) Low risk (breast, colorectal, head and neck)	3.84 1.58 1.00	0.006 0.043	1.47-10.03 1.02-2.46
Prechemotherapy platelet count≥350x109/L	1.83	0.006	1.19-2.83
Hemoglobin level b 100 g/L or use of red cell growth factors	2.31	0.000	1.52-3.51
Prechemotherapy leukocyte count N11x109/L	2.10	0.003	1.30-3.40
BMI ≥ 35 kg/m2	1.83	0.026	1.07-3.13

Leukocytosis and Mortality:

One hundred and thirty 3 patients died during the research study follow-up for an early mortality rate of 3.0%. The typical time to death was 38 days (variety 4-169 days). Early death rate was considerably higher in patients with pre-chemotherapy leukocytosis compared to patients with typical standard leukocyte count. The 150 day mortality rate as approximated by the Kaplan-Meier method in patients with standard leukocytosis was 14.0% (95% CI 8.9-21.6%) compared with 4.4% (95% CI 3.2-6.1%) in patients with regular leukocyte count (Pb0.0001) . Elevation of both absolute neutrophil count and absolute monocyte count prior to initiation of chemotherapy was related to increased threat of early mortality, but elevation of outright lymphocyte count out as not. The death rate in patients who have relentless leukocytosis after the very first cycle of chemotherapy (4.2%) is significantly higher than the mortality rate in patients whose standard leukocytosis deals with (3.8%) and patients with typical leukocyte counts (1.6%) (P = 0.003 for trend). Pre-chemotherapy leukocytosis was related to early death in a multivariate model after adjusting for other clinical variables consisting of age, gender, type of malignancy, phase, Eastern Cooperative Group performance status, VTE pre-chemotherapy platelet count, pre-chemotherapy hemoglobin level, use of erythropoietic promoting representatives, and BMI (HR 2.2, 95% CI 1.5-3.3 p-value b 0.0001).

Leukocytosis, Thrombosis and Mortality:

The highest pre-chemotherapy leukocyte counts were discovered in patients who developed VTE and passed away during study follow-up .

Likewise the greatest early mortality rate was observed in the group of patients with pre-chemotherapy leukocytosis who also developed VTE during study.The mortality rate of 20% in this group was significantly higher than the early mortality rate in the other three groups (Pb0.0001).

Variables Associated with Pre-chemotherapy Leukocytosis:

Several clinical variables were related to pre-chemotherapy leukocytosis in univariate analysis including kind of cancer, male gender, poor performance status, metastatic disease, chronic lung disease, liver problem and weight problems (Pb0.05 for each). In addition, a number of laboratory findings were related to pre-chemotherapy leukocytosis by univariate analysis including thrombocytosis (platelet count ≥ 350 × 109/L), anemia (hemoglobin b10g/dl), raised bilirubin (N1 mg/dl), low albumin (b3.5 g/dl) and hyperglycemia (glucose N120 mg/dl) (Pb0.05 for each). In multivariate analysis, after adjusting for performance status, the type of malignancy, advanced stage (OR 1.3), neutrophil portion N 70%(OR 4.3), raised standard platelet count (OR 2.8), low albumin (OR 1.5), liver disease (OR 1.3), and hyperglycemia (OR 1.3) were associated with pre chemotherapy leukocytosis (Table 3).

Discussion:

Thrombosis is a crucial reason for morbidity and mortality in cancer patients [14,16]. This study shows a strong association in between leukocytosis and increased danger of both thrombosis and early death in a large cohort of cancer patients starting chemotherapy. Previous analyses of the exact same cohort of patients have actually identified pre- chemotherapy leukocytosis as one of 5 clinical elements anticipating increased danger of both VTE [6] and early mortality [18] when adjusting for multiple clinical covariates in multivariate models. Several other groups have confirmed the Khorana risk model anticipates for VTE danger in cancer patients [19,20].

The current study supplies a more in-depth analysis of the relationship between leukocytosis and cancer patient results, and consists of a number of novel findings. Thorough potential collection of information enabled multivariate analysis recognizing numerous clinical elements which are connected with pre-therapy leukocytosis in cancer patients. We also demonstrate that elevation of neutrophil and monocyte counts, however not lymphocyte counts, are very important. These findings enable speculation on potential mechanisms included. We likewise establish a temporal association in between leukocytosis and VTE risk by revealing leukocytosis correlates with apoplexy threat throughout treatment course hence supporting a causative role for leukocytes in mediating VTE in cancer patients. To our understanding this is the only research study to show an association in between leukocytosis and both apoplexy and mortality in the exact same accomplice of cancer patients.

The mechanisms responsible for the associations shown by this analysis are unclear. Leukocytosis might be a marker of an underlying procedure such as more aggressive malignancy, more substantial co-morbidities, or inflammation, or leukocytes might be actively involved in disease progression and cancer-associated apoplexy. The association of leukocytosis with advanced phase and kind of malignancy in this research study might recommend that leukocytosis is identifying patients with more aggressive disease or increased disease problem not caught by other means. This research study likewise reveals that leukocytosis is connected with thrombocytosis, a recognized negative prognostic indicator in patients with cancer [21,22] .In this cohort baseline leukocytosis correlates with numerous clinical findings understood to be connected with underlying inflammation including thrombocytosis [23], hyperglycemia [24,25], hypoalbuminemia [26,27], and transaminitis [28,29]

When adjusting for many of these clinical covariates in multivariate designs leukocytosis remained a considerable predictor of both VTE [6] and early death [18] suggesting that an independent mechanism exists. A current analysis of apoplexy in patients with myeloproliferative neoplasms (MPN) offers a compelling argument that leukocytes have a causative function in MPN-associated apoplexy [30] A comparable argument could be produced leukocytosis and cancer patient outcomes, and numerous mechanisms might be responsible.

Leukocytes may straight contribute to thrombus development and disease progression through release of tissue aspect and vascular endothelial growth factor (VEGF). Tissue element and VEGF levels in leukocytes from patients with cancer are lots of fold higher than in leukocytes from typical controls [31-34], and a recent potential research study in patients with pancreatic cancer demonstrated an association in between leukocyte count and plasma tissue element activity [20] Leukocyte interactions with platelets and endothelium might likewise be important. An elevated level of P-selectin, a protein revealed on activated platelets and associated with platelet leukocyte interactions, is a biomarker for increased risk of cancer-associated thrombosis [35] .It is likewise known that leukocytes produce numerous cytotoxic conciliators like TNF-alpha, IL-1, and interferons which can growth damage [36]. Leukocyte items might also promote a tumor microenvironment which is helpful of thrombus generation, tumor development, chemotherapy, and metastasis resistance [37-40].

There are several restrictions to the current study. The ANC windows registry was created to study issues resulting from chemotherapy induced neutropenia. VTE and mortality were not meant primary endpoints of the initial research study. Data concerning mortality and VTE were prospectively gathered and the study size is adequate for an analysis of this nature. Secondly, just symptomatic VTE events were tape-recorded and research studies recommend that asymptomatic VTE rates are substantially higher [41] Some subgroups of cancer patients such as those with brain or prostate cancer are under-represented, however this accomplice of patients is considerably more diverse than other research studies taking a look at the significance of leukocytosis in cancer patients where most accomplices include only one type of cancer. Last but not least, due to the nature and magnitude of this study biological samples were not collected and saved to allow for more detailed analysis of the mechanisms responsible for the observed associations. This powerful prospective analysis in a large associate of patients will certainly serve to create hypotheses relating to mechanisms and will help direct future studies.

Table 3 Clinical factors associated with pre-chemotherapy leukocytosis by multivariate analysis (n = 4391).

Covariate	Odds Ratio (95% CI)	P-value
Cancer type	–	<.0001
Colorectal (reference)	1.00	–
Gynecologic	1.21 (0.75-1.95)	0.4473
Breast	1.42 (0.94-2.14)	0.0986
Other solid tumors	1.43 (0.91-2.25)	0.1222
Gastric and pancreatic	1.99 (1.02-3.9)	0.0449
Lung	2.07 (1.4-3.04)	0.0002

4. CONCLUSION

In conclusion, clinicians must understand that pre-chemotherapy leukocytosis is associated with substantially increased rates of VTE and early mortality in cancer patients starting chemotherapy. A much better understanding of the function leukocytes play in cancer-associated VTE and cancer progression might allow for interventions such as targeted thromboprophylaxis which might considerably affect cancer patient outcomes. It is likewise possible that more chances for intervention will emerge as we gain a much better understanding of the mechanisms included, and as our ability to manipulate these course ways progresses.

REFERENCES

[1] Yarnell JW, Patterson CC, Sweetnam PM, Lowe GD. Haemostatic/inflammatory markers predict 10-year risk of IHD at least as well as lipids: the Caerphilly collaborative studies.[see comment]. Eur Heart J 2004;25:1049–56.

[2] Brown DW, Ford ES, Giles WH, Croft JB, Balluz LS, Mokdad AH. Associations between white blood cell count and risk for cerebrovascular disease mortality: NHANES II Mortality Study, 1976-1992. Ann Epidemiol 2004;14:425–30.

[3] LandolfiR,DiGennaroL,BarbuiT,DeStefanoV,FinazziG,MarfisiR, etal.European Collaboration on Low-Dose Aspirin in Polycythemia V: Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera. Blood 2007;109: 2446–52.

[4] Carobbio A, Finazzi G, Guerini V, Spinelli O, Delaini F, Marchioli R, et al. Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors, and Jak2 mutation status. Blood 2007;109:2310–3.

[5] Carobbio A, Antonioli E, Guglielmelli P, Vannucchi AM, Delaini F, Guerini V, et al. Leukocytosis and risk stratification assessment in essential thrombocythemia. J Clin Oncol 2008;26:2732–6.

[6] Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 2008;111:4902–7.

[7] Gripp S, Moeller S, Bolke E, Schmitt G, Matuschek C, Asgari S, et al. Survival prediction in terminally ill cancer patients by clinical estimates, laboratory tests, and self-rated anxiety and depression. J Clin Oncol 2007;25:3313–20.

[8] Kasuga I, Makino S, Kiyokawa H, Katoh H, Ebihara Y, Ohyashiki K. Tumor-related leukocytosis is linked with poor prognosis in patients with lung carcinoma. Cancer 2001;92:2399–405.

[9] Maltoni M, Caraceni A, Brunelli C, Broeckaert B, Christakis N, Eychmueller S, et al. Prognostic factors in advanced cancer patients: evidence-based clinical recommendations ,a study by the Steering Committee of the European Association for Palliative Care. J Clin Oncol 2005;23:6240–8.

[10] Ruka W, Rutkowski P, Kaminska J, Rysinska A, Steffen J. Alterations of routine blood tests in adult patients with soft tissue sarcomas: relationships to cytokine serum levels and prognostic significance. Ann Oncol 2001;12:1423–32.

[11] Schmidt H, Suciu S, Punt CJ, Gore M, Kruit W, Patel P, et al. Pretreatment levels of peripheral neutrophils and leukocytes as independent predictors of overall survival in patients with American Joint Committee on Cancer Stage IV Melanoma: results of the EORTC 18951 Biochemotherapy Trial. J Clin Oncol 2007;25:1562–9.

[12] Blom JW, Doggen CJ, Osanto S, Rosendaal FR. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA : J Am Med Asso 2005;293: 715–22.

[13] Heit JA, Silverstein MD, Mohr DN, Petterson TM, O'Fallon WM, Melton III LJ. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med 2000;160:809–15.

[14] Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemostasis : JTH 2007;5:632–4.

[15] PrandoniP,LensingAW,PiccioliA,BernardiE, SimioniP, GirolamiB, etal.Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 2002;100:3484–8.

[16] Prandoni P, Trujillo-Santos J, Surico T, Dalla Valle F, Piccioli A, Monreal M. Investigators R: Recurrent thromboembolism and major bleeding during oral anticoagulant therapy in patients with solid cancer: findings from the RIETE registry. Haematologica 2008;93:1432–4.

[17] Imberti D, Agnelli G, Ageno W, Moia M, Palareti G, Pistelli R, et al. Clinical characteristics and management of cancer-associated acute venous thromboem- bolism: findings from the MASTER Registry. Haematologica 2008;93:273–8.

[18] Kuderer NM, Khorana AA, Francis CW, Culakova E, Ortel TL, Falanga A, et al. Venous Thromboembolism Risk Model Predicts Early Progression and Overall Mortality in Cancer Patients Receiving Chemotherapy. Blood (ASH Annual Meeting Abstracts), vol. 112; 2008. [abstract 172].

[19] Ay C, Chiriac AL, Dunkler D, Vormittag R, Simanek R, Quehenberger P, et al. Biomarkers improve the risk scoring model for prediction of cancer- associated thrombosis. J Thromb Haemost 2009;7.

[20] Price L, Nguyen M, Picozzi R, Kozarek R. ; 2010.

[21] Tomita M, Shimizu T, Hara M, Ayabe T, Onitsuka T. Prognostic impact of thrombocytosis in resectable non-small cell lung cancer. Interact Cardiovasc Thorac Surg 2008;7:613–5.

[22] Suppiah R, Shaheen PE, Elson P, Misbah SA, Wood L, Motzer RJ, et al. Thrombocytosis as a prognostic factor for survival in patients with metastatic renal cell carcinoma. Cancer 2006;107:1793–800.

[23] Klinger MH, Jelkmann W. Role of blood platelets in infection and inflammation. J Interferon Cytokine Res 2002;22:913–22.

[24] Pickup JC, Mattock MB, Chusney GD, Burt D. NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X. Diabetologia 1997;40:1286–92.

[25] Nilsson J, Jovinge S, Niemann A, Reneland R, Lithell H. Relation between plasma tumor necrosis factor-alpha and insulin sensitivity in elderly men with non- insulin-dependent diabetes mellitus. Arterioscler Thromb Vasc Biol 1998;18: 1199–202.

[26] Herrmann FR, Safran C, Levkoff SE, Minaker KL. Serum albumin level on admission as a predictor of death, length of stay, and readmission. Arch Intern Med 1992;152:125–30.

[27] McCluskey A, Thomas AN, Bowles BJ, Kishen R. The prognostic value of serial measurements of serum albumin concentration in patients admitted to an intensive care unit. Anaesthesia 1996;51:724–7.

[28] Clark JM, Brancati FL, Diehl AM. The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol 2003;98:960–7.

[29] Greenfield V, Cheung O, Sanyal AJ. Recent advances in non-alcoholic fatty liver disease. Curr Opin Gastroenterol 2008;24:320–7.

[30] Barbui T, Carobbio A, Rambaldi A, Finazzi G. Perspectives on thrombosis in essential thrombocythemia and polycythemia vera: is leukocytosis a causative factor? Blood 2009;114:759–63.

[31] Kut C, Mac Gabhann F, Popel AS. Where is VEGF in the body? A meta-analysis of VEGF distribution in cancer. Br J Cancer 2007;97:978–85.

[32] Lwaleed BA, Francis JL, Chisholm M. Tissue factor assays as diagnostic tools for cancer? Correlation between urinary and monocyte tissue factor activity. J Hematother Stem Cell Res 1999;8:659–68.

[33] Lwaleed BA, Chisholm M, Francis JL. The significance of measuring monocyte tissue factor activity in patients with breast and colorectal cancer. Br J Cancer 1999; 80:279–85.

[34] Lwaleed BA, Francis JL, Chisholm M. Monocyte tissue factor levels in patients with urological tumors: an association between tumor presence and progression. BJU Int 1999; 83:476–82.

[35] Ay C, Simanek R, Vormittag R, Dunkler D, Alguel G, Koder S, et al. High plasma levels of soluble P-selectin are predictive of venous thromboembolism in cancer patients - results from the Vienna Cancer and Thrombosis Study (CATS). Blood; 2008.

[36] di Carlo E, Iezzi M, Pannellini T, Zaccardi F, Modesti A, Forni G, et al. Neutrophils in anti-cancer immunological strategies: old players in new games. J Hematother Stem Cell Res 2001; 10:739–48.

[37] Coussens LM, Werb Z. Inflammation and cancer.[see comment]. Nature 2002; 420: 860–7.

[38] Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow?. Lancet 2001; 357:539–45.

[39] Mantovani A, Schioppa T, Porta C, Allavena P, Sica A. Role of tumor-associated macrophages in tumor progression and invasion. Cancer Metastasis Rev 2006;25: 315–22.

[40] Sica A, Schioppa T, Mantovani A, Allavena P. Tumor-associated macrophages are a distinct M2 polarized population promoting tumor progression: potential targets of anti-cancer therapy. Eur J Cancer 2006;42:717–27.

[41] Gomes MP, Deitcher SR. Diagnosis of venous thromboembolic disease in cancer patients. Oncology (Huntingt) 2003; 17:126–35 [139; discussion 139-144].